CD86 and neoplasm: Remarkably, the EGFR mutant tumor cells products reduced the expression of HLA‐DR, CD86, and CD80 on DCs compared to WT cells (all p < 0.05) (Figure 1g–j, Figure S3b, Supporting Information), although they did not significantly alter the phagocytic ability of DCs (Figure S3c–g, Supporting Information).